Key result
Rituximab-CHOP and radiation linked to ~80% 5-year progression-free survival in primary mediastinal large B-cell lymphoma.
Population
Patients with Primary mediastinal large B-cell lymphoma (PMBCL)
Design
Review
Authors
Loading...
Supports R-CHOP/CHOP-like plus mediastinal RT in PMBCL; leaves open whether intensive regimens can safely omit radiation.
Rituximab combined with CHOP-like regimens and radiation therapy provides high progression-free survival in PMBCL, though intensive regimens without radiation show promise.
Martelli et al. (2014) conducted a review in Primary mediastinal large B-cell lymphoma (PMBCL). Rituximab with CHOP/CHOP-like regimens and radiation therapy was evaluated on 5-year progression-free survival. Rituximab with CHOP/CHOP-like regimens followed by mediastinal radiation therapy is associated with a 5-year progression-free survival of 75-85% in primary mediastinal large B-cell lymphoma.